Sun Pharma Lands 483 As GMP Deficiencies Continue to Plague Facility

Drug GMP Report
Nearly a year after Sun Pharma began implementing a remediation plan to resolve GMP deficiencies at its Halol, India facility, the FDA continues to fault the company for failing to establish and maintain quality controls in a nine-observation Form 483.

To View This Article:


Subscribe To Drug GMP Report